Search Results

Elanco Animal Health Incorporated announced it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s animal health business, to Vetoquinol SA, a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments.

Saint-Herblain, December 20, 2023 – Valneva SE, a specialty vaccine company, announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting held on December 20, 2023.

Increasing prevalence of diseases in pets, rising pet expenditure, humanization of pets, adoption of online channels for buying pet medicines, and initiatives by key companies are the factors anticipated to fuel the market in the coming years.

According to Report, the Equine Healthcare Market was valued at USD 1.20 Billion in 2021 and it is projected to hit around USD 2.30 Billion by 2030 with a CAGR of 6.82% during the prediction period 2022 to 2030.

The global veterinary medicine market size is expected to surpass around US$ 55.8 billion by 2030 from valued at US$ 30.2 billion in 2020 with CAGR of 8.4% from 2021 to 2030.

The global Equine Pharmaceuticals and Supplements market size is estimated to be worth US$ 1148 million in 2021 and is forecast to a readjusted size of US$ 1568 million by 2030 with a CAGR of 4.5% during the forecast period 2022-2030.